Discovery of HIV-1 Integrase Inhibitors
Furan and Sulfonamide-based Integrase Inhibitors
978-3-639-30281-3
3639302818
60
2010-11-18
49,00 €
eng
https://images.our-assets.com/cover/230x230/9783639302813.jpg
https://images.our-assets.com/fullcover/230x230/9783639302813.jpg
https://images.our-assets.com/cover/2000x/9783639302813.jpg
https://images.our-assets.com/fullcover/2000x/9783639302813.jpg
Highly active antiretroviral therapy (HAART) is the current treatment regimen for HIV/AIDS, a disease that has claimed millions worldwide. HAART is a cocktail that inhibits different stages of the viral life cycle targeting protease, reverse transcriptase, and often includes anti-fusion inhibitor enfurvitide. The addition of HIV-1 integrase (IN) inhibitor raltegravir to HAART reveals a decrease of the virus to near undetectable levels in treatment-experienced patients. Although these successes are encouraging for antiviral therapy, specific mutations resistant to raltegravir have also appeared. Drug resistant mutations is the inevitable signature of HIV with a merry-go-round history of antiviral drug development and viral evolution, highlighting the need to identify new leads for IN inhibition. Absent of a cellular
https://morebooks.de/books/hu/published_by/vdm-verlag-dr-mueller/3/products
Gyógyszerészet
https://morebooks.de/store/hu/book/discovery-of-hiv-1-integrase-inhibitors/isbn/978-3-639-30281-3